Lorbrena (lorlatinib) — United Healthcare

Initial criteria

• Diagnosis of inflammatory myofibroblastic tumor (IMT)
• Disease is ALK-positive

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Lorbrena therapy

Approval duration

12 months